example of summary of research paper hamlet as tragic hero essay brand name cialis cheap click here best time to take crestor medication american museum of natural history essay living a healthy lifestyle essay viagra manufacturers india https://ncappa.org/term/free-graphic-organizers-for-writing-essays/4/ l-carnitine and cialis antiquing too much viagra ad should assisted suicide legalized essay certified resume writing services rip van winkle essay themes https://willherndon.org/pharmaceutical/too-much-lipitor/24/ levitra del tropico panama case study evaluation average age men taking viagra watch doctoral literature review see https://kirstieennisfoundation.com/dysfunction/clomid-birth-defects-lawsuit/35/ bahaya sildenafil sitrat https://equalitymi.org/citrate/oral-jelly-viagra-uk/29/ https://naes.unr.edu/barrios/wp-content/?done=many-pages-700-words-essay huck finn essay questions https://efm.sewanee.edu/faq/method-of-problem-solving/22/ source link get link cialis tadalafil contents arnold cialis doxycycline malaria price peerless laser processors case study Research Scientist with the BC Centre on Substance Use (BCCSU)
Dr. M-J Milloy is a Research Scientist with the BC Centre on Substance Use (BCCSU) and the Canopy Growth Professor in Cannabis Science at the University of British Columbia. He is a substance use epidemiologist whose past research has focused on the interrelationships between illicit drugs and HIV—including HIV treatment patterns among people who use illicit drugs (PWUD) and adherence to HIV treatment among incarcerated PWUD—as well as the effects of cannabis on people living with HIV or addiction.
He’s the principal investigator of the AIDS Care Cohort to Evaluate exposure to Survival Services (ACCESS) study, a prospective cohort of people living with HIV who use illicit drugs, and the Vancouver Cannabis Dispensary Study. He’s authored more than 150 peer-reviewed articles including studies in high-impact journals including Addiction, AIDS, and The Lancet. In 2011, he authored a study in The Lancet showing that the establishment of Insite, Vancouver’s first supervised injection facility, preceded a 35% decline in rates of fatal overdose in the Downtown Eastside compared to 9% in the rest of the City of Vancouver.